Reports Q3 revenue $49.298M vs $36.062M last year. “We closed two transformational transactions during the quarter, the divestiture of our Passenger business and the acquisition of Keystone Perfusion, setting us up incredibly well for long term growth and value creation,” said Melissa Tomkiel, Co-CEO and General Counsel. “Organic revenue growth accelerated to 29.0% in Q3, well above our expectation for mid-teens revenue growth in the second half of the year, resulting in record Adjusted EBITDA performance.”
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SRTA:
- Is BLDE a Buy, Before Earnings?
- Cathie Wood Pours into Veracyte Stake ahead of Earnings Beat, Slashes Biotech Holdings
- Strata Critical Medical price target raised to $7.25 from $6.50 at Lake Street
- Strata Critical Medical Completes Keystone Acquisition
- Strata completes acquisition of Keystone Perfusion